In a phase II trial in patients with T2D, 26 weeks of treatment with tirzepatide demonstrated dramatically superior results relative to a specific once-weekly GLP1R agonist in both HbA1c and body weight lowering194. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.